← Back to Clinical Trials
Recruiting NCT03347227

Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation

Trial Parameters

Condition Atrial Fibrillation
Sponsor Ottawa Heart Institute Research Corporation
Study Type INTERVENTIONAL
Phase N/A
Enrollment 502
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2018-08-24
Completion 2024-12
Interventions
Catheter ablation

Brief Summary

A multicentre, parallel group, two arm, single-blinded randomized clinical trial, assessing the efficacy of a patient-tailored catheter ablation (CA) strategy guided by atrial scar mapping in addition to pulmonary vein isolation (PVI) when compared to PVI alone in patients with persistent atrial fibrillation (AF).

Eligibility Criteria

Inclusion Criteria: 1. Age ≥18 years ; 2. Subjects with symptomatic persistent AF AND clinically indicated catheter ablation for AF 3. At least one episode of AF that is sustained beyond 3 months in duration ; documented on 12-lead ECG, Holter monitor, loop monitor or trans-telephonic monitor (TTM) within 36 months of enrollment in the study; 4. Modified DR-FLASH score \>=4 4\. Subjects must be able to provide informed consent. Exclusion Criteria: 1. History of previous catheter ablation for AF or left atrial flutter; 2. History of previous surgical ablation for AF; 3. Known intracardiac thrombus; 4. Contraindication to systemic oral anticoagulation therapy; 5. Reversible causes of AF; 6. Hypertrophic cardiomyopathy; 7. Severe valvular disease (mitral/aortic stenosis or regurgitation); 8. Subjects that are pregnant or breastfeeding; 9. Comorbid condition with life expectancy \< 1 year

Related Trials